Nadine Anaizi, PA
Physician Assistant · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 1
- 1 carrier
- Offices
- 4
On the public record
- California licence: Delinquent
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Nadine Anaizi’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A56459 · Delinquent
Licence status: Delinquent · since 1996 · expires 2022-07-31 · Shiraz University Faculty of Medicine Aka Pahlavi University.
License renewal fee has not been paid. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$15,005
Medicare paid this office $15,005 for 75 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 70 | $13,847 | $131 |
| Return visit (30+ min) | 14 | $1,159 | $83 |
Who their Medicare patients are
75 Original Medicare patients in 2024. Average age 68 · Women 51% · Also on Medicaid 27% · Health risk score 1.93. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 63% · Coronary heart disease 28% · Depression 27% · Diabetes 23% · Chronic kidney disease 21% · Cancer 17% · Atrial fibrillation 17% · Stroke 15%.
The office billed $97,473, Medicare allowed $20,227 and paid $15,005; for 120 services of 2 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 75 | 120 | 68 | 1.93 | $97,473 | $15,005 |
| 2023 | 66 | 99 | 69 | 1.46 | $75,424 | $10,569 |
| 2022 | 50 | 69 | 66 | 1.25 | $51,515 | $5,796 |
| 2021 | 50 | 83 | 67 | 1.63 | $61,035 | $7,757 |
| 2020 | 26 | 35 | 64 | 1.28 | $17,773 | $2,557 |
| 2019 | 36 | 41 | 65 | 1.79 | $6,056 | $1,609 |
| 2018 | 84 | 105 | 66 | 1.94 | $19,477 | $5,318 |
| 2017 | 63 | 97 | 66 | 1.69 | $12,676 | $3,695 |
| 2016 | 80 | 122 | 64 | 1.64 | $24,125 | $5,731 |
| 2015 | 86 | 108 | 64 | 1.75 | $37,230 | $7,287 |
| 2014 | 89 | 112 | 65 | 1.59 | $39,430 | $7,421 |
| 2013 | 49 | 74 | 62 | 1.73 | $22,165 | $4,283 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Long return visit (40+ min) | 60 | $9,909 | $109 |
2022: 2 services
| Long return visit (40+ min) | 33 | $4,070 | $102 |
| Return visit (30+ min) | 20 | $1,599 | $59 |
2021: 2 services
| Long return visit (40+ min) | 39 | $6,298 | $110 |
| Return visit (30+ min) | 15 | $1,178 | $65 |
2020: 1 service
| Long return visit (40+ min) | 22 | $1,909 | $80 |
2019: 2 services
| Return visit (30+ min) | 13 | $520 | $37 |
| Short return visit (20+ min) | 16 | $407 | $25 |
2018: 5 services
| Return visit (30+ min) | 22 | $1,156 | $50 |
| New patient visit (45+ min) | 11 | $909 | $83 |
| Return visit (30+ min) | 15 | $825 | $49 |
| Short return visit (20+ min) | 19 | $624 | $31 |
| Short return visit (20+ min) | 17 | $605 | $32 |
2017: 4 services
| Return visit (30+ min) | 23 | $1,134 | $44 |
| Short return visit (20+ min) | 24 | $1,002 | $32 |
| Return visit (30+ min) | 15 | $725 | $45 |
| Short return visit (20+ min) | 19 | $615 | $31 |
2016: 4 services
| Return visit (30+ min) | 34 | $1,753 | $49 |
| Short return visit (20+ min) | 26 | $1,002 | $33 |
| Return visit (30+ min) | 18 | $924 | $51 |
| Short return visit (20+ min) | 23 | $769 | $33 |
2015: 3 services
| New patient visit (45+ min) | 25 | $2,435 | $97 |
| Return visit (30+ min) | 34 | $2,418 | $64 |
| Short return visit (20+ min) | 33 | $1,344 | $38 |
2014: 4 services
| New patient visit (45+ min) | 27 | $2,777 | $103 |
| Return visit (30+ min) | 16 | $1,288 | $61 |
| Short return visit (20+ min) | 27 | $1,225 | $38 |
| New patient visit (30+ min) | 20 | $1,100 | $55 |
2013: 4 services
| Short return visit (20+ min) | 21 | $1,396 | $44 |
| New patient visit (45+ min) | 13 | $1,289 | $99 |
| Return visit (30+ min) | 14 | $898 | $56 |
| New patient visit (30+ min) | 11 | $523 | $48 |
Drugs they prescribed that Part D paid
$164,809
Pharmacies billed $164,809 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 114) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
69 generic and 45 brand-name prescriptions · $164,809 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Apriso | 12 | $6,022 | $502 |
| Mesalamine | 21 | $5,233 | $249 |
| Omeprazole | 14 | $64 | $5 |
Year by year
| 2024 | 114 | 38 | 0% (0) | 39% | $164,809 |
| 2023 | 110 | 40 | 0% (0) | 45% | $266,926 |
| 2022 | 352 | 69 | 0% (0) | None | $1,899,274 |
| 2021 | 419 | 73 | None | 48% | $1,554,509 |
| 2020 | 328 | 64 | 0% (0) | 40% | $1,011,373 |
| 2019 | 1,004 | 263 | None | None | $859,424 |
| 2018 | 1,609 | 345 | None | 23% | $838,867 |
| 2017 | 1,441 | 311 | 1% (18) | None | $833,545 |
| 2016 | 1,237 | 283 | None | 31% | $589,836 |
| 2015 | 1,184 | 286 | None | 29% | $458,960 |
| 2014 | 1,195 | 290 | None | 32% | $502,953 |
| 2013 | 552 | 180 | None | 35% | $179,061 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Mesalamine | 17 | $12,036 | $708 |
2022: 10 drugs
| Stelara | 53 | $1,434,706 | $27,070 |
| Humira(Cf) | 14 | $166,116 | $11,865 |
| Entyvio | 11 | $88,916 | $8,083 |
| Xeljanz | 11 | $66,015 | $6,001 |
| Mesalamine | 47 | $42,118 | $896 |
| Balsalazide Disodium | 22 | $6,816 | $310 |
| Apriso | 12 | $5,565 | $464 |
| Budesonide Dr | 20 | $2,362 | $118 |
| Budesonide Ec | 13 | $1,919 | $148 |
| Omeprazole | 23 | $430 | $19 |
2021: 13 drugs
| Stelara | 40 | $1,022,910 | $25,573 |
| Humira(Cf) | 15 | $184,313 | $12,288 |
| Pentasa | 22 | $48,962 | $2,226 |
| Mesalamine | 62 | $46,207 | $745 |
| Budesonide Ec | 23 | $7,220 | $314 |
| Apriso | 12 | $5,881 | $490 |
| Balsalazide Disodium | 20 | $4,597 | $230 |
| Budesonide Dr | 21 | $3,910 | $186 |
| Mercaptopurine | 11 | $1,734 | $158 |
| Sulfasalazine | 12 | $544 | $45 |
| Methotrexate | 11 | $358 | $33 |
| Prednisone | 16 | $190 | $12 |
| Omeprazole | 17 | $105 | $6 |
2020: 13 drugs
| Stelara | 19 | $454,765 | $23,935 |
| Humira(Cf) | 40 | $376,654 | $9,416 |
| Mesalamine | 41 | $32,736 | $798 |
| Creon | 13 | $23,563 | $1,813 |
| Balsalazide Disodium | 24 | $8,350 | $348 |
| Budesonide Ec | 18 | $7,568 | $420 |
| Apriso | 11 | $5,807 | $528 |
| Mercaptopurine | 18 | $4,419 | $246 |
| Diphenoxylate-Atropine | 16 | $917 | $57 |
| Sulfasalazine | 15 | $824 | $55 |
| Azathioprine | 11 | $678 | $62 |
| Methotrexate | 16 | $659 | $41 |
| Prednisone | 15 | $182 | $12 |
2019: 23 drugs
| Stelara | 12 | $274,820 | $22,902 |
| Humira | 33 | $169,387 | $5,133 |
| Mesalamine | 75 | $80,061 | $1,067 |
| Asacol Hd | 14 | $42,750 | $3,054 |
| Creon | 24 | $34,434 | $1,435 |
| Budesonide Ec | 19 | $12,723 | $670 |
| Dexilant | 18 | $12,196 | $678 |
| Linzess | 21 | $11,392 | $542 |
| Balsalazide Disodium | 19 | $4,593 | $242 |
| Mercaptopurine | 28 | $3,003 | $107 |
| Pantoprazole | 188 | $2,418 | $13 |
| Omeprazole | 130 | $2,269 | $17 |
| Rabeprazole | 27 | $1,997 | $74 |
| Misoprostol | 15 | $1,554 | $104 |
| Polyethylene Glycol 3350 | 13 | $1,249 | $96 |
| Loperamide | 20 | $1,153 | $58 |
| Ranitidine | 54 | $738 | $14 |
| Esomeprazole Magnesium | 14 | $678 | $48 |
| Azathioprine | 14 | $539 | $38 |
| Famotidine | 27 | $453 | $17 |
| Sucralfate | 12 | $418 | $35 |
| Colestipol | 11 | $376 | $34 |
| Gavilyte-G | 20 | $249 | $12 |
2018: 32 drugs
| Humira | 38 | $221,141 | $5,820 |
| Mesalamine | 88 | $80,205 | $911 |
| Creon | 46 | $59,636 | $1,296 |
| Alosetron | 12 | $25,959 | $2,163 |
| Budesonide Ec | 51 | $23,849 | $468 |
| Dexilant | 22 | $11,992 | $545 |
| Linzess | 19 | $11,015 | $580 |
| Balsalazide Disodium | 35 | $10,544 | $301 |
| Ursodiol | 17 | $9,378 | $552 |
| Apriso | 16 | $7,800 | $487 |
| Polyethylene Glycol 3350 | 75 | $6,365 | $85 |
| Esomeprazole Magnesium | 41 | $5,203 | $127 |
| Amitiza | 13 | $4,809 | $370 |
| Mercaptopurine | 61 | $4,722 | $77 |
| Pantoprazole | 236 | $3,793 | $16 |
| Vancomycin | 16 | $3,563 | $223 |
| Rabeprazole | 41 | $3,429 | $84 |
| Omeprazole | 217 | $3,374 | $16 |
| Ranitidine | 57 | $3,213 | $56 |
| Loperamide | 34 | $1,863 | $55 |
| Sulfasalazine Dr | 21 | $1,612 | $77 |
| Misoprostol | 12 | $1,358 | $113 |
| Sucralfate | 21 | $808 | $38 |
| Famotidine | 51 | $771 | $15 |
| Azathioprine | 22 | $726 | $33 |
| Duloxetine | 11 | $533 | $48 |
| Ondansetron Odt | 24 | $465 | $19 |
| Mirtazapine | 12 | $459 | $38 |
| Dicyclomine | 28 | $435 | $16 |
| Gavilyte-G | 36 | $428 | $12 |
| Ondansetron | 14 | $194 | $14 |
| Metronidazole | 11 | $153 | $14 |
2017: 34 drugs
| Humira | 40 | $203,510 | $5,088 |
| Creon | 39 | $58,533 | $1,501 |
| Mesalamine | 58 | $47,639 | $821 |
| Asacol Hd | 23 | $36,879 | $1,603 |
| Nexium | 32 | $26,389 | $825 |
| Alosetron | 12 | $23,438 | $1,953 |
| Lialda | 12 | $22,626 | $1,886 |
| Ursodiol | 36 | $21,940 | $609 |
| Dexilant | 18 | $13,165 | $731 |
| Carafate | 33 | $12,823 | $389 |
| Budesonide Ec | 21 | $12,625 | $601 |
| Vancomycin | 28 | $11,221 | $401 |
| Balsalazide Disodium | 25 | $10,137 | $405 |
| Mercaptopurine | 67 | $6,269 | $94 |
| Linzess | 17 | $6,042 | $355 |
| Polyethylene Glycol 3350 | 57 | $3,514 | $62 |
| Esomeprazole Magnesium | 26 | $3,351 | $129 |
| Sulfasalazine Dr | 34 | $3,196 | $94 |
| Diphenoxylate-Atropine | 27 | $2,915 | $108 |
| Omeprazole | 148 | $2,738 | $19 |
| Pantoprazole | 176 | $2,295 | $13 |
| Rabeprazole | 18 | $2,140 | $119 |
| Ranitidine | 39 | $2,073 | $53 |
| Loperamide | 17 | $1,582 | $93 |
| Azathioprine | 24 | $1,203 | $50 |
| Duloxetine | 13 | $756 | $58 |
| Famotidine | 43 | $499 | $12 |
| Sucralfate | 11 | $468 | $43 |
| Ondansetron | 15 | $421 | $28 |
| Dicyclomine | 35 | $410 | $12 |
| Mirtazapine | 16 | $357 | $22 |
| Gavilyte-G | 25 | $321 | $13 |
| Ciprofloxacin | 13 | $185 | $14 |
| Metoclopramide | 25 | $106 | $4 |
2016: 33 drugs
| Humira | 35 | $153,893 | $4,397 |
| Asacol Hd | 31 | $67,277 | $2,170 |
| Creon | 27 | $42,077 | $1,558 |
| Lialda | 29 | $26,045 | $898 |
| Canasa | 11 | $21,526 | $1,957 |
| Mesalamine | 21 | $20,316 | $967 |
| Ursodiol | 25 | $18,893 | $756 |
| Nexium | 29 | $17,764 | $613 |
| Dexilant | 24 | $17,182 | $716 |
| Delzicol | 14 | $15,795 | $1,128 |
| Vancomycin | 18 | $13,606 | $756 |
| Budesonide Ec | 19 | $13,591 | $715 |
| Balsalazide Disodium | 16 | $8,254 | $516 |
| Amitiza | 17 | $8,051 | $474 |
| Carafate | 22 | $8,036 | $365 |
| Mercaptopurine | 60 | $6,630 | $110 |
| Linzess | 12 | $3,912 | $326 |
| Sulfasalazine Dr | 29 | $2,999 | $103 |
| Omeprazole | 169 | $2,018 | $12 |
| Pantoprazole | 176 | $1,879 | $11 |
| Polyethylene Glycol 3350 | 34 | $1,663 | $49 |
| Diphenoxylate-Atropine | 17 | $1,581 | $93 |
| Loperamide | 16 | $1,289 | $81 |
| Rabeprazole | 21 | $1,257 | $60 |
| Dicyclomine | 46 | $818 | $18 |
| Azathioprine | 21 | $743 | $35 |
| Ondansetron | 17 | $574 | $34 |
| Sucralfate | 14 | $470 | $34 |
| Lansoprazole | 11 | $436 | $40 |
| Gavilyte-G | 18 | $304 | $17 |
| Ranitidine | 19 | $288 | $15 |
| Famotidine | 22 | $150 | $7 |
| Prednisone | 11 | $133 | $12 |
2015: 29 drugs
| Asacol Hd | 53 | $88,940 | $1,678 |
| Humira | 13 | $62,972 | $4,844 |
| Budesonide Ec | 34 | $38,430 | $1,130 |
| Creon | 33 | $33,548 | $1,017 |
| Pentasa | 27 | $31,730 | $1,175 |
| Nexium | 34 | $16,509 | $486 |
| Xifaxan | 15 | $16,416 | $1,094 |
| Delzicol | 17 | $16,055 | $944 |
| Ursodiol | 32 | $14,212 | $444 |
| Vancomycin | 12 | $12,731 | $1,061 |
| Balsalazide Disodium | 25 | $9,250 | $370 |
| Mesalamine | 13 | $7,072 | $544 |
| Amitiza | 16 | $6,228 | $389 |
| Carafate | 14 | $4,940 | $353 |
| Mercaptopurine | 56 | $4,572 | $82 |
| Sulfasalazine Dr | 33 | $3,158 | $96 |
| Omeprazole | 212 | $2,366 | $11 |
| Polyethylene Glycol 3350 | 37 | $1,930 | $52 |
| Pantoprazole | 122 | $1,700 | $14 |
| Lansoprazole | 26 | $1,340 | $52 |
| Azathioprine | 16 | $1,206 | $75 |
| Loperamide | 14 | $1,159 | $83 |
| Ranitidine | 23 | $481 | $21 |
| Gavilyte-G | 23 | $349 | $15 |
| Dicyclomine | 27 | $266 | $10 |
| Metronidazole | 17 | $263 | $15 |
| Famotidine | 18 | $233 | $13 |
| Prednisone | 11 | $206 | $19 |
| Allopurinol | 11 | $109 | $10 |
2014: 35 drugs
| Asacol Hd | 53 | $58,011 | $1,095 |
| Humira | 14 | $50,282 | $3,592 |
| Pentasa | 50 | $34,702 | $694 |
| Cimzia | 12 | $33,368 | $2,781 |
| Budesonide Ec | 26 | $24,548 | $944 |
| Creon | 44 | $23,556 | $535 |
| Delzicol | 22 | $18,452 | $839 |
| Canasa | 15 | $15,636 | $1,042 |
| Lialda | 20 | $9,955 | $498 |
| Ursodiol | 17 | $9,608 | $565 |
| Nexium | 19 | $9,078 | $478 |
| Balsalazide Disodium | 18 | $5,596 | $311 |
| Omeprazole | 214 | $3,105 | $15 |
| Pantoprazole | 103 | $2,079 | $20 |
| Ondansetron | 19 | $1,775 | $93 |
| Sulfasalazine Dr | 20 | $1,699 | $85 |
| Lansoprazole | 20 | $1,294 | $65 |
| Mercaptopurine | 25 | $1,267 | $51 |
| Polyethylene Glycol 3350 | 33 | $1,078 | $33 |
| Azathioprine | 23 | $670 | $29 |
| Loperamide | 12 | $479 | $40 |
| Gavilyte-G | 22 | $355 | $16 |
| Dicyclomine | 14 | $276 | $20 |
| Pentoxifylline | 17 | $265 | $16 |
| Famotidine | 20 | $265 | $13 |
| Peg-3350 and Electrolytes | 18 | $255 | $14 |
| Ranitidine | 15 | $250 | $17 |
| Baclofen | 16 | $248 | $15 |
| Metronidazole | 13 | $210 | $16 |
| Mirtazapine | 11 | $195 | $18 |
| Nortriptyline | 12 | $189 | $16 |
| Metoclopramide | 15 | $147 | $10 |
| Hydroxyzine | 11 | $103 | $9 |
| Prochlorperazine Maleate | 13 | $86 | $7 |
| Amitriptyline | 12 | $74 | $6 |
2013: 19 drugs
| Humira | 13 | $42,045 | $3,234 |
| Pentasa | 22 | $19,409 | $882 |
| Creon | 27 | $16,621 | $616 |
| Asacol Hd | 17 | $14,745 | $867 |
| Budesonide Ec | 11 | $14,253 | $1,296 |
| Canasa | 14 | $9,279 | $663 |
| Delzicol | 13 | $5,806 | $447 |
| Nexium | 13 | $5,514 | $424 |
| Lansoprazole | 19 | $2,326 | $122 |
| Omeprazole | 74 | $1,342 | $18 |
| Pantoprazole | 32 | $672 | $21 |
| Sulfasalazine | 14 | $618 | $44 |
| Polyethylene Glycol 3350 | 11 | $583 | $53 |
| Ondansetron | 12 | $437 | $36 |
| Azathioprine | 17 | $431 | $25 |
| Metronidazole | 12 | $252 | $21 |
| Ranitidine | 11 | $222 | $20 |
| Dicyclomine | 19 | $147 | $8 |
| Prednisone | 12 | $131 | $11 |
Money from drug and device companies
$27 in 2022
A payment is not proof that care is biased.
| Janssen Biotech | Stelara | $27 | 1 payment
|
See the published payment
| Janssen Biotech | Meals · 2022-08-15 | Stelara | $27 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1164752515
- Licence
- CA 56459, NY 013816California A56459: Delinquent · expires 2022-07-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X); Physician assistant, medical (363AM0700X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2010-01-07
- NPI last updated
- 2025-12-23
- NPI record certified
- 2025-12-23
This is when the NPI record was last certified, not a medical board exam.